Status:

COMPLETED

A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-Biologic and/or Biologic DMARDS

Lead Sponsor:

Hoffmann-La Roche

Collaborating Sponsors:

Clalit Health Services

Conditions:

Rheumatoid Arthritis

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

This single arm, open-label study will evaluate the efficacy and safety of RoActemra/Actemra (tocilizumab) in patients with active, moderate to severe rheumatoid arthritis who have an inadequate respo...

Eligibility Criteria

Inclusion

  • Adult patients, \>/=18 years of age
  • Active moderate to severe rheumatoid arthritis
  • Inadequate response to \>/=3 DMARDs (non-biologic and/or biologic)
  • Current treatment at stable dose for \>/=8 weeks
  • Etanercept discontinued \>/=2 weeks, Anakinra \>/=1 week, Infliximab, Adalimumab, Abatacept, Golimumab, Certolizumab \>/=4 weeks, prior to baseline visit. Patients have discontinued MabThera/Rituxan or Ocrelizumab \>/=16 weeks, and must have proven B-cell repletion

Exclusion

  • Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following baseline
  • Rheumatic autoimmune disease other than RA
  • Functional class IV (American College of Rheumatology Classification)
  • Prior history or current inflammatory joint disease other than RA
  • Oral corticosteroids at a dose of \>10 mg/day prednisone equivalent
  • Positive hepatitis B surface antigen (HBsAg) and / or total hepatitis B core antibodies (HBcAb) or hepatitis C virus (HCV) antibody
  • Current or history of recurrent bacterial, viral, fungal or mycobaterial infection
  • History of or currently active primary or secondary immunodeficiency

Key Trial Info

Start Date :

October 1 2010

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 1 2014

Estimated Enrollment :

145 Patients enrolled

Trial Details

Trial ID

NCT01149057

Start Date

October 1 2010

End Date

July 1 2014

Last Update

November 2 2016

Active Locations (16)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 4 (16 locations)

1

Afula, Israel, 18101

2

Ashkelon, Israel, 78306

3

Beer Yaakov, Israel, 6093000

4

Beersheba, Israel, 8410101

A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-Biologic and/or Biologic DMARDS | DecenTrialz